Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 3,350.00p 40 05:00:01
Bid Price Offer Price High Price Low Price Open Price
3,250.00p 3,450.00p 3,350.00p 3,350.00p 3,350.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.58 -39.64 -31.84 2,228.8

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
17/1/201915:31(Chi-Med)Hutchinson China Meditech Limited1,789
31/7/201806:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201809:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201706:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:45:003,428.00401,371.20O
2019-01-23 16:20:493,320.002006,640.00O
2019-01-23 16:20:023,318.601003,318.60O
2019-01-23 16:12:463,318.6026862.84O
2019-01-23 16:03:003,360.001505,040.00O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

DateSubject
24/1/2019
08:20
Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 3,350p.
Hutchison China Meditech has a 4 week average price of 3,185p and a 12 week average price of 3,185p.
The 1 year high share price is 5,670p while the 1 year low share price is currently 3,185p.
There are currently 66,532,683 shares in issue and the average daily traded volume is 6,426 shares. The market capitalisation of Hutchison China Meditech is £2,228,844,880.50.
10/1/2019
15:46
robert longcroft: Haved followed Nerds of steel for some fair time now & appreciate his positive view on this company even when it has taken such a bashing. Bit concerned as to how low price will be driven before it bottoms out. I note the share price is just starting to wain again this afternoon. Rob longcroft
10/1/2019
14:56
lauders: See HCM are participating in this per their website: 18 Jan 2019 Bloomberg Intelligence - Harnessing China Biotech’s Potential Bloomberg Hong Kong Office Https://www.chi-med.com/investors/event-information/ Let's hope we start to climb back up share price wise soon!
13/12/2018
08:12
nhb001: Still at a £1+ discount to the US share price.
16/11/2018
11:08
lauders: Quite miti 1000! Whether you believe what the IC say or not here is their take on the news: IC TIP UPDATES: It’s been a morning of clinical trial failures across the pharmaceutical industry, but one of the biggest casualties is Hutchison China Meditech (HCM), which has revealed its final-phase trial of fruquintinib in China has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small cell lung cancer patients. This marked one of four important drug trials for Chi-Med, as it hopes to build on fruquintinib’s commercial launch (the drug has already been approved to treat advanced colorectal cancer). It’s a big disappointment - evident in the 15 per cent share price drop in early trading - but chairman Simon To says he still has long-term faith in the drug, as well as the other trials currently underway. We see this morning’s de-rating as a second buying opportunity. Also note the AZ news today and the IC's feedback on the same page. Https://www.investorschronicle.co.uk/shares/2018/11/16/news-tips-hutchison-china-meditech-imperial-brands-astrazeneca-more/
01/11/2018
07:19
nerdofsteel: Volume always seems to increase significantly prior to significant pipeline news.....apart from Fruquintinib approval where absolutely nothing happened with regard to the share price!
14/9/2018
19:55
sportii: Chi-med share price has not been moving in the positive direction, even after the major news of first drug approval. Due to the unfortunate geopolitical situation, institutional buyers in the USA are not showing any interest. Hence, share price is suffering and we, long time holders, are disappointed. Unless, there are new buyers who are willing to buy, share price will not move up. That will be the case even if the company gets approval for two or more drug candidates. Wondering why the management isn’t interested in listing on HK stock exchange.
07/9/2018
07:34
sportii: Any early falls in the share price going to bevtransient. Expecting ‘corrections’ by this afternoon.
07/9/2018
06:51
reptile3: kazoom.... I should have said with reference to the drop on Nasdaq where at 8.30p.m. UK time the share price was 9.3% down on the day and therefore anticipating the drop to around £41 on AIM.
06/9/2018
17:59
sportii: Everything else, other than the share price, appears positive. Big drop in share price on the other side of the pond, today. Is yesterdsy’s approval news not good enough for the big buyers? Disheartened sellers, perhaps.
15/3/2018
16:43
dbadvn: Had a very interesting meeting with the CFO . They are certainly sticking to plan and gearing up for European/US sales independently of whatever happens with Lilley etc. Making all the right noises on Clinical/ Sales teams/ Branding/ Competition and realistic on timescale. Not defending the fact that the recent cash raise was basically opportunistic use of perfect market conditions . Looking to be cash flow positive within 5 years ( doe not exclude more cash raising depending on opportunities). The positive "elephant in the room" is the $50bn potential of HMPL 523 in the immunology market. Although still at the early stages HCM seem to have the lead here and only Gilead as competition. Short term lack of news flow may see the share price drift but medium and long term potential probabilities of success are increasing . At some point the US market will start to valur HCM in the same way as the US Biotechs ( less the takeover premium perhaps ) .At that point the share price will react strongly . When that happens is anyones guess so I for one am staying invested long term
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
LSE
HCM
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190124 10:25:51